Join the Talvey group to help and get support from people like you.
Talvey News
Talquetamab Plus Teclistamab Shows Promise in Multiple Myeloma
THURSDAY, Jan. 9, 2025 – For patients with relapsed or refractory multiple myeloma, talquetamab plus teclistamab shows response in a high percentage of patients and a higher incidence of grade 3 or...
FDA Approves Talvey (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma
HORSHAM, Pa., Aug. 10, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Talvey™ (ta...